Grifols (GIKLY) Income from Continuing Operations (2010 - 2020)

Grifols (GIKLY) reported Income from Continuing Operations of 330091015.77 for Q1 2020, up 69.41% on a YoY basis from 194843192.77 in Q2 2019, and down 55.46% quarter-over-quarter from 741176413.24 in Q4 2019.

Grifols (GIKLY) Income from Continuing Operations (2010 - 2020) Analysis & Trends

Grifols has reported Income from Continuing Operations for 10 years, with the latest figure at 330091015.77 in Q1 2020.

  • For the quarter ending Q1 2020, Income from Continuing Operations rose 69.41% year-over-year to 330091015.77; the trailing twelve-month figure through Mar 2020 stood at 2068492905.63 (up 35.91% YoY), and the FY2025 full-year result was 582021757.35, up 155.71% from the prior year.
  • Income from Continuing Operations for Q1 2020 stood at 330091015.77, down from 741176413.24 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 882309060.91 in Q4 2017, with the low at 101201471.58 in Q4 2016.
  • Historically, Income from Continuing Operations has averaged 356556002.65 across 5 years, with a median of 260548010.52 in 2018.
  • Annual changes were most pronounced in 2016 — Income from Continuing Operations tumbled 170.51% — and 2017, when it jumped 971.83%.
  • Grifols' Income from Continuing Operations stood at 101201471.58 in 2016, then jumped by 971.83% to 882309060.91 in 2017, then declined by 9.06% to 802382283.85 in 2018, then fell by 7.63% to 741176413.24 in 2019, then slumped by 55.46% to 330091015.77 in 2020.
  • The last three Income from Continuing Operations figures came in at 330091015.77 (Q1 2020), 741176413.24 (Q4 2019), and 194843192.77 (Q1 2019), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn 3.30 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 7.40 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 5.24 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 697.00 Mn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn -4.21 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 1.82 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 2.02 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 2.71 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 2.68 Bn
10 Grifols - - - -

Historic Data

Download Data
DateValue
Mar 31, 2020 330.09 Mn
Dec 31, 2019 741.18 Mn
Mar 31, 2019 194.84 Mn
Dec 31, 2018 802.38 Mn
Jun 30, 2018 260.55 Mn
Mar 31, 2018 264.14 Mn
Dec 31, 2017 882.31 Mn
Jun 30, 2017 255.10 Mn
Mar 31, 2017 247.88 Mn
Dec 31, 2016 -101.20 Mn
Sep 30, 2016 227.94 Mn
Jun 30, 2016 202.82 Mn
Mar 31, 2016 327.20 Mn
Dec 31, 2015 143.52 Mn
Sep 30, 2015 227.51 Mn
Jun 30, 2015 215.29 Mn
Mar 31, 2015 221.20 Mn
Sep 30, 2013 166.11 Mn
Jun 30, 2013 176.26 Mn
Mar 31, 2013 165.42 Mn